Becky Mingyao Ma

Abstract The Hong Kong Genome Project (HKGP) aims to build a foundational resource for precision medicine in the Chinese population through large-scale genome sequencing and integrated analyses. Here we report findings from over 20,000 HKGP participants across two cohorts: a rare disease cohort including 2,227 patients with suspected genetic diseases and a population cohort including 18,261 participants undergoing genomic screening for medically actionable findings.

Get full text access Log in, subscribe or purchase for full access. References 1. Gagnon-Sanschagrin, P ∙ Liang, Y ∙ Sanon, M ∙ et al. Excess healthcare costs in patients with autosomal dominant polycystic kidney disease by renal dysfunction stage J Med Econ. 2021; 24:193-201 2. Blanchette, CM ∙ Iorga, ŞR ∙ Altan, A ∙ et al. Healthcare resource utilization and costs associated with autosomal dominant polycystic kidney disease J Health Econ Outcomes Res. 2014; 2:63-74 3.